Stock Alert: Allogene (ALLO) Trades 5.19% Higher June 22

Equities Staff  |

Today, Allogene Therapeutics Inc (NASDAQ:ALLO) rose $0.59 to close Wednesday at $11.96.

The company began the day at $11.22 and shares fluctuated between $12.21 and $11.06 with 2,227,298 shares trading hands.

Allogene is averaging 2,466,764 shares traded over the last 30 days. They have shed 23.79% YTD.

Allogene anticipates its next earnings on 2022-08-03.

For technical charts, analysis, and more on Allogene visit the company profile.

About Allogene Therapeutics Inc

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

To get more information on Allogene Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Allogene Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content